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Abstract
Background: The level of soluble vascular endothelial growth factor receptor 1 (sVEGFR1) is increased in sepsis
and strongly associated with disease severity and mortality. Endothelial activation and damage contribute to both
sepsis and trauma pathology. Therefore, this study measured sVEGFR1 levels in trauma patients upon hospital
admission hypothesizing that sVEGFR1 would increase with higher injury severity and predict a poor outcome.
Methods: Prospective observational study of 80 trauma patients admitted to a Level I Trauma Centre. Data on
demography, biochemistry, Injury Severity Score (ISS), transfusions and 30-day mortality were recorded and plasma/
serum (sampled a median of 68 min (IQR 48-88) post-injury) was analyzed for sVEGFR1 and biomarkers reflecting
sympathoadrenal activation (adrenaline, noradrenaline), tissue injury (histone-complexed DNA fragments, hcDNA),
endothelial activation and damage (von Willebrand Factor Antigen, Angiopoietin-2, soluble endothelial protein C
receptor, syndecan-1, soluble thrombomodulin (sTM)), coagulation activation/inhibition and fibrinolysis
(prothrombinfragment 1 + 2, protein C, activated Protein C, tissue-type plasminogen activator, plasminogen
activator inhibitor-1, D-dimer) and inflammation (interleukin-6). Spearman correlations and regression analyses to
identify variables associated with sVEGFR1 and its predictive value.
Results: Circulating sVEGFR1 correlated with injury severity (ISS, rho = 0.46), shock (SBE, rho = -0.38; adrenaline, rho
= 0.47), tissue injury (hcDNA, rho = 0.44) and inflammation (IL-6, rho = 0.54) (all p < 0.01) but by multivariate linear
regression analysis only lower SBE and higher adrenaline and IL-6 were independent predictors of higher sVEGFR1.
sVEGFR1 also correlated with biomarkers indicative of endothelial glycocalyx degradation (syndecan-1, rho = 0.67),
endothelial cell damage (sTM, rho = 0.66) and activation (Ang-2, rho = 0.31) and hyperfibrinolysis (tPA, rho = 0.39;
D-dimer, rho = 0.58) and with activated protein C (rho = 0.31) (all p < 0.01). High circulating sVEGFR1 correlated
with high early and late transfusion requirements (number of packed red blood cells (RBC) at 1 h (rho = 0.27, p =
0.016), 6 h (rho = 0.27, p = 0.017) and 24 h (rho = 0.31, p = 0.004) but was not associated with mortality.
Conclusions: sVEGFR1 increased with increasing injury severity, shock and inflammation early after trauma but only
sympathoadrenal activation, hypoperfusion, and inflammation were independent predictors of sVEGFR1 levels.
sVEGFR1 correlated strongly with other biomarkers of endothelial activation and damage and with RBC transfusion
* Correspondence: sisse.ostrowski@gmail.com
1Section for Transfusion Medicine, Capital Region Blood Bank, Copenhagen
University Hospital, Rigshospitalet, Blegdamsvej 9, Copenhagen DK-2100,
Denmark
Full list of author information is available at the end of the article
Ostrowski et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2012, 20:27
http://www.sjtrem.com/content/20/1/27
© 2012 Ostrowski et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.requirements. Sympathoadrenal activation, shock and inflammation may be critical drivers of endothelial activation
and damage early after trauma.
Keywords: Trauma, Endothelium, Endothelial cells, Glycocalyx, Soluble vascular growth factor receptor 1, sVEGFR1,
sFlt-1, Syndecan-1, Adrenaline, Catecholamines, Sympathoadrenal activation
Introduction
Critical illness accompanied by shock is associated with
endothelial activation and damage, evidenced by high
circulating levels of molecules derived from the
endothelium such as adhesion and signaling receptors,
glycocalyx constituents and Weibel-Palade body con-
tents [1,2]. In severely injured patients, high circulating
Angiopoietin (Ang)-2 [3], syndecan-1 [4-6], a glycocalyx
constituent [7], and soluble thrombomodulin (sTM)
[4,8] are indicators of endothelial activation, glycocalyx
degradation and endothelial cell damage, respectively;
events that contribute directly to trauma pathology by
enhancing vascular permeability, hypocoagulability and
hyperfibrionlysis in the circulating blood [9-11]. Conse-
quently, high levels of Ang-2, syndecan-1 and sTM all
predict a poor outcome in trauma patients [3,4,6,8].
Sepsis is another life threatening condition where
endothelial disruption, due in part to hyperinflammation
and shock, contributes directly to disease pathology
[12-14], so high circulating levels of endothelial derived
biomarkers also here predict a poor clinical outcome
[15]. In a recent study [16], Shapiro and colleagues
investigated biomarkers of endothelial activation in 221
adult patients presenting with clinical suspicion of infec-
tion, of whom approximately 1/3 developed severe sep-
sis and 1/3 septic shock. Among several biomarkers,
soluble vascular endothelial growth factor (VEGF) recep-
tor 1 (sVEGFR1) (also called soluble fms-like tyrosine
kinase 1, sFlt-1) had the strongest association with
SOFA score (r = 0.66, p < 0.001) and the highest area
under the receiver operator characteristic curve for
severe sepsis (0.82) and mortality (0.91) [16].
sVEGFR1 is the truncated soluble form of the mem-
brane bound VEGFR1, which is expressed primarily by
endothelial cells and which, together with VEGF, com-
prise the VEGF-VEGFR system. This system is one of
two vascular specific receptor Tyr kinase systems, the
second one being the Ang-Tie (Tyr kinase with Ig and
EGF homology domains) system [17]. By competing
with membrane bound VEGFR1, sVEGFR1 acts as a
competitive inhibitor of VEGF signaling in endothelial
cells, being a critical regulator of circulating VEGF bioa-
vailability. Thus, sVEGFR1 exerts antiangiogenic, antiin-
flammatory and vascular stabilizing functions, the latter
by interfering with VEGF-induced increases in vascular
permeability [18]. Since the circulating level of VEGF is
increased in sepsis, it was recently suggested that the
early rise in sVEGFR1 in patients whom later develop
sepsis, severe sepsis or septic shock, reflects a critical
component of the anti-inflammatory host response [16].
Given that endothelial activation and damage are critical
hallmarks of both trauma and sepsis pathology [9-14] and
that several potential drivers of endothelial disruption are
present in both conditions (shock, hyperinflammation, cir-
culating histones [19,20]), the aim of the present study
was to investigate the circulating level and predictive value
of sVEGFR1 early after trauma, due to the strong predic-
tive value of this biomarker in sepsis [16]. Also, we investi-
gated potential drivers of sVEGFR1 and sVEGFR1
interrelations with a broad range of endothelial derived
biomarkers indicative of endothelial activation, Weibel-
Palade body release, endothelial cell damage and glycoca-
lyx degradation/shedding, hypothesizing that the level of
sVEGFR1 would increase with trauma severity and with
the level of sympathoadrenal activation in accordance with
previous finding from our group [4].
Materials and methods
Study design
Prospective observational cohort study of trauma patients
admitted directly to a Level I Trauma Centre (TC) at a
tertiary hospital (Rigshospitalet, Copenhagen, Denmark,
covering 2.5 million inhabitants) between March 2010
and November 2010. The study is part of an ongoing lar-
ger multicentre study, Activation of Coagulation and
Inflammation after Trauma 3 (ACIT3) [21], approved by
the Regional Ethics Committee (H-4-2009-139), the Dan-
ish Data Protection Agency and conducted in accordance
with the 2nd Declaration of Helsinki. Written informed
consent was obtained from the patients or next of kin.
Here we report on findings related to a cohort of 80
patients recruited to the ACIT3 study who had extensive
blood samples performed. Data from this cohort have
previously been published [22-24].
Patient selection
ACIT3 study inclusions: Adult trauma patients (≥ 18
years) who met criteria for full trauma team activation
and had an arterial cannula inserted. The latter was
chosen since only patients with expected severe injuries
have an arterial cannula placed immediately upon TC
admission. Exclusion criteria were arrival in the TC > 2
hours after injury; > 2,000 ml of intravenous fluids
administered before hospital arrival; transfer from
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Patients were retrospectively excluded if they were tak-
ing anticoagulant/antiplatelet medications (except
aspirin); had moderate or severe liver disease or had
known bleeding diathesis.
T h e8 0i n c l u d e dp a t i e n t sw e r es e l e c t e df r o mt h ef i r s t
100 patients recruited to the ACIT3 study with com-
plete data. We intended to include 80 patients because
we measured an extensive number of biomarkers by
ELISA, with each ELISA kit providing analysis of 80
s a m p l e s .W ea i m e da ti n c l u d i n gt h em o s ts e v e r e l y
injured and/or coagulopathic patients and selected the
80 patients according to: Outcome (mortality or ICU
admission post trauma; yes), transfusion of RBC within
6 hours (yes), RTS (< 5.00, we had not access to ISS
before later in the study period) or coagulopathy (APTT
≥ 35 sec, INR ≥ 1.2, Ly30 > 1%/Cl30 < 95%; yes). This
yielded 70 severely injured/coagulopathic patients, and
additionally 10 patients (age 48 years (IQR 43-52), 60%
males) were selected blinded from the remaining 30
patients to match their age and gender (see Table 1 for
details on demography, injury severity etc.). The 20
patients not included in this study, had, compared to
the included patients, comparable age and gender (41
years (IQR 33-53), 40% males) and APTT (26 (IQR 23-
27), NS) but had, as expected, lower ISS (4 (IQR 2-10),
p < 0.001), mortality (0%, p = 0.037) and INR (1.1 (IQR
1.0-1.1), p = 0.007).
Data on demography, clinical and biochemical para-
meters, investigations, management and 30-day mortal-
ity were recorded and ISS scores were obtained from
t h eT r a u m aA u d i t&R e s e a r c hN e t w o r k( T A R N )
database.
No patients received tranexamic acid, adrenaline or
noradrenaline prior to blood sampling.
Blood sampling
Blood was sampled immediately upon arrival for stan-
dard arterial blood gas (ABG, Radiometer ABL 725/735,
Copenhagen, Denmark), routine biochemistry and
research analyses (citrate, heparin, EDTA plasma,
serum). Routine biochemistry samples were analyzed in
a DS/EN ISO 15189 standardized laboratory by a Sys-
mex XE-2100 (hemoblobin, platelets, leukocytes) and
ACL TOP (APTT, INR, AT, fibrinogen). Plasma samples
were ice-cooled immediately whereas serum samples
were kept at RT for 1 h before centrifugation (one
(serum) or two (plasma) times 1800 g at 5°C for 10
min) and storage at -80°C.
Enzyme linked immunosorbent assay (ELISA)
measurements
sVEGFR1 in addition to soluble biomarkers of sym-
pathoadrenal activation, tissue damage, endothelial cell
activation and damage, endothelial glycocalyx degrada-
tion/shedding, coagulation activation/inhibition and
inflammation were measured in uniplicate by commer-
cially available immunoassays in serum/plasma accord-
ing to the manufactures recommendations. EDTA
plasma: sVEGFR1 (Quantikine, R&D Systems Europe,
Ltd., Abingdon, UK; LLD 3.5 pg/ml); adrenaline and
noradrenaline (2-CAT ELISA, Labor Diagnostica Nord
GmbH & Co. KG, Nordhorn, Germany; lower limit of
detection (LLD) 11 pg/ml (adrenaline, normal reference
< 100 pg/ml) and 44 pg/ml (noradrenaline, normal
reference < 600 pg/ml), respectively. Histone-complexed
DNA fragments (hcDNA, Cell Death Detection ELISA-
PLUS, Roche, Hvidovre, Denmark; LLD not stated, rela-
tive quantification); soluble thrombomodulin (sTM)
(Nordic Biosite, Copenhagen, Denmark; LLD 0.38 ng/
ml); angiopoietin-2 (Ang-2, R&D Systems Europe; LLD
8.29 pg/ml); D-dimer (ADI; LLD 2-4 ng/ml). Citrate
plasma: protein C (PC, Helena Laboratories, Beaumont,
TX, US; LLD 5% of reference plasma); activated protein
C (APC, USCNLIFE; LLD 4.2 pg/ml); soluble endothelial
Table 1 Demography, injury severity, biochemistry,
hemostasis, transfusion requirements and mortality in 80
trauma patients admitted directly to a Level I Trauma
Centre at a tertiary hospital (Rigshospitalet, Copenhagen,
Denmark) and included as part of a prospective
Multicentre study, Activation of Coagulation and
Inflammation after Trauma 3 (ACIT3)
Patients
N8 0
Age yrs 46 (33-64)
Gender male % 68% (54)
Blunt trauma % (n) 91% (73)
ISS score 17 (10-28)
sTBI % (n) 31% (22)
GCS pre-hospital score 13 (6-15)
pH 7.34 (7.29-7.39)
SBE mmol/l -2.0 (-4.0-0.0)
Lactate mmol/l 1.7 (1.2-2.7)
SatO2 pre-hospital % 98 (93-100)
Shock index pre-hospital HR/SBP 0.62 (0.50-0.75)
Hemoglobin mmol/l 8.4 (7.3-9)
Platelet count 10
9/l 208 (173-253)
APTT > 35 sec % 8% (6)
INR > 1.2 % 13% (10)
Saline pre-hospital ml 350 (0-1,000)
MT (> 10 RBCs in 24 h) % (n) 14% (11)
Mortality % (n) 18% (14)
Data are presented as medians (IQR) or n (%). ISS, injury severity score; sTBI,
severe Traumatic Brain Injury, Abbreviated Injury Score head > 3; PH, pre-
hospital at the site of injury; GCS, Glascow Coma Score scale; RBC, red blood
cells; APTT, activated partial thromboplastin time; INR, international
normalized ratio; MT, massive transfusion > 10 red blood cell units the initial
24 hours.
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0.064 ng/ml); tissue-type plasminogen activator (tPA,
ADI, detects sc-tPA, tc-tPA and tPA/PAI-1 complexes;
LLD 1 ng/ml); plasminogen activator inhibitor-1 (PAI-1,
Assaypro; LLD 0.2 ng/ml); prothrombinfragment 1 and
2 (PF1.2, USCNLIFE; LLD 0.043 nmol/l); von Willeb-
rand Factor antigen (vWF, Helena Laboratories, LLD 5%
of reference plasma); interleukin-6 (IL-6, Quantikine HS,
R&D Systems Europe; LLD 0.039 pg/ml). Serum: Synde-
can-1 (Diaclone SAS, Besancon, France; LLD 2.56 ng/
ml). In each patient, all 16 biomarkers were measured
corresponding to a total of 16*80 = 1,280 measurements,
with only 3 missing measurements (0.2%).
Statistics
Statistical analysis was performed using SAS 9.1 (SAS
Institute Inc., Cary, NC, US). Correlations were investi-
gated by Spearman correlations and presented by rho
and p-values. To investigate the impact of injury sever-
ity, shock, tissue damage and inflammation on the
sVEGFR1 level, the contribution of ISS, SBE, adrenaline,
hcDNA and IL-6 to the variation in sVEGFR1 was
investigated by univariate and multivariate linear regres-
sion analysis, presented by regression coefficients b with
(standard errors), t- and p-values and R
2 for the multi-
variate model. The association between sVEGFR1 and
30-day mortality was investigated by logistic regression
analysis. Data are presented as medians with inter quar-
tile ranges (IQR). P-values < 0.05 were considered
significant.
Results
Patients
The present study included 80 trauma patients with ISS
in the entire range (median 17 (IQR 10-28); ISS > 26 n
=2 3 ,1 5 - 2 6n=2 6a n d<1 5n=3 0 ) ,t h em a j o r i t ys u f -
fering from blunt trauma and approximately one third
had severe traumatic brain injury (sTBI, Abbreviated
Injury Score head > 3) (Table 1). Most patients (96%)
were referred by mobile emergency care units staffed
with anesthetists (28% by helicopter) and blood samples
were drawn a median of 68 min (IQR 48-88) after the
injury. Twelve patients (15%) had increased APTT and/
or INR, 14% received massive transfusion (> 10 RBC
units the initial 24 hours) and overall 30-day mortality
was 18% (Table 1). By thrombelastography (TEG), 11%
had a hypercoagulable TEG (increased clot strength), 1%
a hypocoagulable TEG (reduced clot stregnth) and 1%
had hyperfibrinolysis [22].
sVEGFR1 levels in trauma patients
In blood sampled on admission from severely injured
trauma patients, high circulating soluble VEGF receptor
1 (sVEGFR1) levels correlated with high injury severity
(ISS; rho = 0.46, p < 0.001), shock (SBE; rho = -0.38, p
= 0.001 and adrenaline; rho = 0.47, p < 0.001), high cir-
culating levels of histones/DAMPs (histone-complexed
DNA fragments, rho = 0.44, p < 0.001) and inflamma-
tion (IL-6; rho = 0.54, p < 0.001) (Table 2 univariate
analysis). In the multivariate linear regression analysis,
however, only lower SBE and higher adrenaline and IL-6
were independently associated with higher sVEGFR1
(Table 2) suggesting that shock (hypoperfusion, sym-
pathoadrenal activation) and inflammation were critical
drivers of high sVEGFR1 levels after trauma. In accor-
dance with this notion, sVEGFR1 also correlated with
pre-hospital shock index (pulse rate/systolic blood pres-
sure, rho = 0.28, p = 0.001). Furthermore, sVEGFR1 was
lower in patients with sTBI as compared to non-sTBI
patients (median 146 pg/ml (IQR 131-202) vs. 220 pg/
ml (IQR 153-275), p = 0.011).
sVEGFR1, endothelial disruption and coagulopathy
sVEGFR1 also correlated positively with biomarkers
indicative of endothelial glycocalyx degradation (synde-
can-1, Figure 1A), endothelial cell damage (sTM, Figure
1B) and activation (Ang-2 and tPA, Figure 1C-D)
whereas it did not correlate with vWF (rho = -0.12, NS)
or sEPCR (rho = -0.02, NS).
In addition to drivers and biomarkers directly derived
from the endothelium, sVEGFR1 also correlated with
noradrenaline (rho = 0.25, p = 0.026), D-dimer (rho =
0.58, p < 0.001) and activated protein C (Figure 1E)
whereas it did not correlate with the non-activated form
of protein C (Figure 1F) or PF1.2 (rho = 0.04, NS).
sVEGFR1 did not correlate with hemoglobin or plate-
let count (data not shown), but correlated strongly with
leukocyte count (rho = 0.42, p < 0.001) and glucose (rho
Table 2 Univariate and multivariate linear regression
analysis of variables associated with sVEGFR1 in trauma
patients upon admission to a Level I Trauma Centre
Univariate Multivariate (R
2 = 0.38)
Unit b (SE) t-
value
p-
value
b (SE) t-
value
p-
value
ISS point 3.33
(0.95)
3.5 <
0.001
-1.38
(1.43)
-1.0 0.340
SBE mmol/
l
-13.8
(3.3)
-4.3 <
0.001
-7.9 (3.5) -2.3 0.027
Adrenaline ng/ml 34.7
(8.1)
4.3 <
0.001
20.1
(10.0)
2.0 0.048
hcDNA % 1.97
(0.71)
2.8 0.007 0.12
(0.81)
0.1 0.886
IL-6 pg/ml 1.13
(0.21)
5.4 <
0.001
0.98
(0.29)
3.3 0.001
Regression coefficients (b) with standard errors (SE), t- and p-values and R
2
displayed for the multivariate model. P-values are shown in bold for variables
with p < 0.05. Predicted change in sVEGFR1 (pg/ml) associated with one unit
increase in injury severity score (ISS), SBE (mmol/l), circulating adrenaline (ng/
ml), hcDNA (%) and IL-6 (pg/ml).
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degree of sympathoadrenal activation. sVEGFR1 did not
correlate with APTT, INR, fibrinogen or TEG variables
R-time, a angle, maximum amplitude or clot lysis (Ly30,
Ly60) (data not shown).
sVEGFR1 and transfusion requirements
High circulating levels of sVEGFR1 correlated with both
early and late transfusion requirements (number of RBC
transfusions 1 h (rho = 0.27, p = 0.016), 6 h (rho = 0.27,
p = 0.017) and 24 h (rho = 0.31, p = 0.004) after admis-
sion). The sVEGFR1 level did not differ between survi-
vors and non-survivors and it did not associate with 30-
day mortality (data not shown).
Discussion
In this study, sympathoadrenal activation, hypoperfusion
and inflammation were independently associated with
high circulating sVEGFR1 levels early after trauma and
sVEGFR1 correlated positively with biomarkers indica-
tive of endothelial glycocalyx degradation (syndecan-1),
endothelial cell damage (sTM) and Weibel-Palade body
degranulation (tPA, Ang-2). High sVEGFR1 levels corre-
lated with high early and late transfusion requirements
but did not associate with mortality.
Tissue trauma undoubtedly contributes directly to
endothelial injury in trauma, but the concurrent exces-
sive sympathoadrenal activation [4,25], hypoperfusion
[8] and inflammation [26] present in shocked trauma
patients also induce systemic endothelial activation and
damage [9,10]. Hypoxia is a potent inducer of endothe-
lial activation [27] and catecholamines also induce active
release of procoagulant and profibrinolytic factors from
the endothelium [28,29] and in high concentrations,
they directly damage the endothelium [9,30,31] in accor-
dance with the recent finding that high circulating adre-
naline early after trauma is independently associated
with high syndecan-1 levels [25]. In line with this, the
present study found that high circulating adrenaline was
independently associated with high sVEGFR1, even after
adjusting for injury severity, hcDNA, hypoperfusion and
inflammation. Though the level of VEGF is reported
unchanged and unaffected by injury severity and shock
early after trauma [3], the finding here that sVEGFR1
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Figure 1 Correlations between sVEGFR1 and biomarkers of endothelial activation and damage and protein C activation on admission
in 80 trauma patients. Spearman correlations with rho and p-values are shown for: A) sVEGFR1 (pg/ml) vs. Syndecan-1 (ng/ml), B) sVEGFR1
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inflammation suggests that the bioavailability of VEGF
may change early after trauma. Notably, patients with
sTBI had lower circulating sVEGFR1 as compared to
non-sTBI trauma patients. The potential (patho)physio-
logic effects, if any, of these findings however remains to
be determined.
In accordance with previous studies reporting of
strong interrelations between different endothelial bio-
markers in trauma [3] and sepsis [16], sVEGFR1 corre-
lated with other endothelial derived biomarkers in this
study. Importantly, sVEGFR1 was strongly positively
correlated with both syndecan-1 and sTM, biomarkers
of endothelial glycocalyx degradation/shedding and
endothelial cell damage, respectively, and both carrying
prognostic value in trauma patients [4,6,8]. Also,
sVEGFR1 correlated with Ang-2 and tPA, which are
both Weibel-Palade constituents [29] and inducers of
fibrinolysis and enhanced vascular permeability, and
with activated protein C, a potent natural anticoagulant
and inducer of fibrinolysis. Considering Ang-2, this is
increased early after trauma and associated with poor
clinical outcome [3]. Ang-2 is expressed almost exclu-
sively by endothelial cells and is induced dramatically
and released instantaneously from Weibel-Palade bodies
upon endothelial activation [17,29,32] and its release
results in rapid (autocrine) destabilization of the
endothelium which, through endothelial activation and
increased vascular permeability, triggers an inflamma-
tory response [17,32].
Despite the interrelation between sVEGFR1 and other
endothelial activation and damage biomarkers in accor-
dance with the finding in sepsis by Shapiro et al [16],
sVEGFR1 did not associate with mortality as observed
in sepsis. Whether this is due to a type II error due to
the low number of subjects investigated in the present
study or reflects biologic differences between the trauma
and sepsis populations remains to be determined.
Given the finding that sVEGFR1 correlated with trans-
fusion requirements, it should be emphasized that all
biochemistry variables and biomarkers were measured
in arrival blood samples taken before administration of
any blood products and hence sampled before any
potential introduction of bias (e.g., content of sVEGFR1
in blood products). Though sVEGFR1 correlated with
transfusion requirements, it did not correlate with any
TEG variables.
It may seem counterintuitive that active release of
endothelial derived molecules in the most severely
injured and potentially bleeding trauma patients pro-
motes progressive hypocoagulability in the circulating
blood [4,10,11,25,33-36] through induction of endogen-
ous anticoagulation (activated protein C, sTM), hyperfi-
brinolysis (tPA, activated protein C) [8,11] and
heparinization (glycocalyx shedding) [4,9,37]. We
recently hypothesized that this progressive hypocoagul-
ability, from a systems biology perspective, reflects an
evolutionary adapted response that counterbalances the
progressively more damaged and procoagulant endothe-
lium in order to keep the microcirculation open [9].
Furthermore, several of the endothelial derived mole-
cules that promote hypocoagulability exert potent anti-
inflammatory and cytoprotective functions [13,38-40]
that may ultimately generate at survival advantage in
injured individuals [41]. In addition to progressive hypo-
coagulability, severe trauma is associated with increased
vascular permeability which, in part, may result from
downstream effects of glycocalyx degradation [42,43]
and Ang-2 release [17,32]. In a context without resusci-
tation (from an evolutionary perspective) the increase in
vascular permeability may generate a survival advantage
since the rapid shift of volume from the intra- to the
extra-vascular compartment in a bleeding subject may
both lower blood pressure and contain fluid within the
body for latter mobilization if the subject survives,
which seems favorable as compared to bleeding out a
large un-replaceable intravascular volume. Such
response (or a more exaggerated one) may, however,
not generate the same survival benefit in a context with
aggressive volume resuscitation and life support in
severely injured individuals and this may explain the
consistent finding that the highest levels of several
endothelial derived molecules are negatively associated
with outcome in trauma [3-6,8].
The results presented here are subject to the limita-
tions inherent to observational studies and, thereby, do
not allow independent evaluation of the cause-and-effect
relationship suggested. Furthermore, the low number of
subjects, and especially the low number of severely
injured patients, included in the present study increases
t h er i s ko fi n t r o d u c i n gat y p eI Ie r r o ra n dt h em u l t i p l e
testing increases the risk of a type I error, emphasizing
that the reported findings should be confirmed in a lar-
ger cohort of patients.
Conclusions
The present study demonstrated that the level of
sVEGFR1 early after trauma increased with increasing
injury severity, sympathoadrenal activation, hypoperfu-
sion and inflammation. Furthermore, we found strong
interrelations between sVEGFR1 and circulating levels
of other endothelial derived biomarkers. In severely
injured patients, endothelial activation and disruption
promote progressive hypocoagulability and enhanced
vascular permeability and may increase the systemic
level of soluble antiinflammatory and cytoprotective
mediators, events that may contribute to reduce bleed-
ing and maintain blood flow in the microcirculation and
Ostrowski et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2012, 20:27
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Page 6 of 8thereby from an evolutionary perspective generate a sur-
vival advantage.
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